vs
Ultragenyx Pharmaceutical Inc.（RARE）与RESOURCES CONNECTION, INC.（RGP）财务数据对比。点击上方公司名可切换其他公司
Ultragenyx Pharmaceutical Inc.的季度营收约是RESOURCES CONNECTION, INC.的1.8倍（$207.3M vs $117.7M），RESOURCES CONNECTION, INC.净利率更高（-10.8% vs -62.0%，领先51.3%），Ultragenyx Pharmaceutical Inc.同比增速更快（25.9% vs -19.2%），RESOURCES CONNECTION, INC.自由现金流更多（$15.6M vs $-100.8M），过去两年Ultragenyx Pharmaceutical Inc.的营收复合增速更高（38.0% vs -11.8%）
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
RGP原名 Resources Global Professionals，是 Resources Connection, Inc. 的核心运营主体，面向全球客户提供多领域专业咨询服务，覆盖财务会计、信息管理、治理风险合规、人力资本、法务监管、企业咨询与重组、战略传播以及供应链管理等板块。
RARE vs RGP — 直观对比
损益表 — Q4 FY2025 vs Q2 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $207.3M | $117.7M |
| 净利润 | $-128.6M | $-12.7M |
| 毛利率 | — | 37.1% |
| 营业利润率 | -54.7% | -10.3% |
| 净利率 | -62.0% | -10.8% |
| 营收同比 | 25.9% | -19.2% |
| 净利润同比 | 3.5% | 81.6% |
| 每股收益（稀释后） | $-1.28 | $-0.38 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $207.3M | $117.7M | ||
| Q3 25 | $159.9M | $120.2M | ||
| Q2 25 | $166.5M | $139.3M | ||
| Q1 25 | $139.3M | $129.4M | ||
| Q4 24 | $164.6M | $145.6M | ||
| Q3 24 | $139.5M | $136.9M | ||
| Q2 24 | $147.0M | $148.2M | ||
| Q1 24 | $108.8M | $151.3M |
| Q4 25 | $-128.6M | $-12.7M | ||
| Q3 25 | $-180.4M | $-2.4M | ||
| Q2 25 | $-115.0M | $-73.3M | ||
| Q1 25 | $-151.1M | $-44.1M | ||
| Q4 24 | $-133.2M | $-68.7M | ||
| Q3 24 | $-133.5M | $-5.7M | ||
| Q2 24 | $-131.6M | $10.5M | ||
| Q1 24 | $-170.7M | $2.5M |
| Q4 25 | — | 37.1% | ||
| Q3 25 | — | 39.5% | ||
| Q2 25 | — | 40.2% | ||
| Q1 25 | — | 35.1% | ||
| Q4 24 | — | 38.5% | ||
| Q3 24 | — | 36.5% | ||
| Q2 24 | — | 40.2% | ||
| Q1 24 | — | 37.0% |
| Q4 25 | -54.7% | -10.3% | ||
| Q3 25 | -106.9% | -1.7% | ||
| Q2 25 | -64.8% | -47.0% | ||
| Q1 25 | -102.6% | -38.4% | ||
| Q4 24 | -74.3% | -52.7% | ||
| Q3 24 | -94.6% | -3.5% | ||
| Q2 24 | -79.1% | 7.6% | ||
| Q1 24 | -151.9% | 2.8% |
| Q4 25 | -62.0% | -10.8% | ||
| Q3 25 | -112.8% | -2.0% | ||
| Q2 25 | -69.0% | -52.6% | ||
| Q1 25 | -108.5% | -34.0% | ||
| Q4 24 | -80.9% | -47.2% | ||
| Q3 24 | -95.7% | -4.2% | ||
| Q2 24 | -89.5% | 7.1% | ||
| Q1 24 | -156.8% | 1.7% |
| Q4 25 | $-1.28 | $-0.38 | ||
| Q3 25 | $-1.81 | $-0.07 | ||
| Q2 25 | $-1.17 | $-2.21 | ||
| Q1 25 | $-1.57 | $-1.34 | ||
| Q4 24 | $-1.34 | $-2.08 | ||
| Q3 24 | $-1.40 | $-0.17 | ||
| Q2 24 | $-1.52 | $0.31 | ||
| Q1 24 | $-2.03 | $0.08 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $421.0M | $89.8M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $-80.0M | $194.6M |
| 总资产 | $1.5B | $289.3M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q4 25 | $421.0M | $89.8M | ||
| Q3 25 | $202.5M | $77.5M | ||
| Q2 25 | $176.3M | $86.1M | ||
| Q1 25 | $127.1M | $72.5M | ||
| Q4 24 | $174.0M | $78.2M | ||
| Q3 24 | $150.6M | $89.6M | ||
| Q2 24 | $480.7M | $108.9M | ||
| Q1 24 | $112.3M | $113.8M |
| Q4 25 | $-80.0M | $194.6M | ||
| Q3 25 | $9.2M | $206.4M | ||
| Q2 25 | $151.3M | $207.1M | ||
| Q1 25 | $144.2M | $277.8M | ||
| Q4 24 | $255.0M | $325.7M | ||
| Q3 24 | $346.8M | $407.2M | ||
| Q2 24 | $432.4M | $418.8M | ||
| Q1 24 | $140.3M | $414.9M |
| Q4 25 | $1.5B | $289.3M | ||
| Q3 25 | $1.2B | $287.2M | ||
| Q2 25 | $1.3B | $304.7M | ||
| Q1 25 | $1.3B | $375.6M | ||
| Q4 24 | $1.5B | $424.9M | ||
| Q3 24 | $1.5B | $512.9M | ||
| Q2 24 | $1.6B | $510.9M | ||
| Q1 24 | $1.3B | $523.2M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-99.8M | $15.9M |
| 自由现金流经营现金流 - 资本支出 | $-100.8M | $15.6M |
| 自由现金流率自由现金流/营收 | -48.6% | 13.2% |
| 资本支出强度资本支出/营收 | 0.5% | 0.3% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-472.0M | $24.3M |
8季度趋势，按日历期对齐
| Q4 25 | $-99.8M | $15.9M | ||
| Q3 25 | $-91.4M | $-7.8M | ||
| Q2 25 | $-108.3M | $16.8M | ||
| Q1 25 | $-166.5M | $659.0K | ||
| Q4 24 | $-79.3M | $1.8M | ||
| Q3 24 | $-67.0M | $-309.0K | ||
| Q2 24 | $-77.0M | $3.2M | ||
| Q1 24 | $-190.7M | $20.5M |
| Q4 25 | $-100.8M | $15.6M | ||
| Q3 25 | $-92.7M | $-8.0M | ||
| Q2 25 | $-110.7M | $16.5M | ||
| Q1 25 | $-167.8M | $238.0K | ||
| Q4 24 | $-79.5M | $61.0K | ||
| Q3 24 | $-68.6M | $-575.0K | ||
| Q2 24 | $-79.0M | $3.0M | ||
| Q1 24 | $-193.9M | $20.4M |
| Q4 25 | -48.6% | 13.2% | ||
| Q3 25 | -58.0% | -6.6% | ||
| Q2 25 | -66.5% | 11.8% | ||
| Q1 25 | -120.5% | 0.2% | ||
| Q4 24 | -48.3% | 0.0% | ||
| Q3 24 | -49.2% | -0.4% | ||
| Q2 24 | -53.7% | 2.1% | ||
| Q1 24 | -178.2% | 13.5% |
| Q4 25 | 0.5% | 0.3% | ||
| Q3 25 | 0.8% | 0.1% | ||
| Q2 25 | 1.5% | 0.2% | ||
| Q1 25 | 1.0% | 0.3% | ||
| Q4 24 | 0.1% | 1.2% | ||
| Q3 24 | 1.2% | 0.2% | ||
| Q2 24 | 1.4% | 0.1% | ||
| Q1 24 | 3.0% | 0.1% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 0.30× | ||
| Q1 24 | — | 8.04× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
RGP
| US | $93.7M | 80% |
| Non Us | $24.0M | 20% |
